The occurence, the biological, biochemical and immunological properties of spontaneous inactivating inhibitors (directed against factors VIII, V or XIII) and of interfering inhibitors (inhibiting prothrombin activation) are reviewed. The clinical implications and therapy of these inhibitors are discussed with special reference to the management of patients with spontaneous factor VIII inhibitors.